The ␤-amyloid (A␤) peptide is present both in serum and in platelets, however it is unclear whether A␤ plays a role in platelet function. We have now investigated the effects of soluble A␤ on platelet function and have found that low levels (0.1-1 nM) of soluble A␤ augment ADP-dependent platelet aggregation and translocation of focal adhesion kinase to the platelet cytoskeleton. Addition of A␤ to gel-filtered platelets along with concentrations of adenosine diphosphate (ADP) producing submaximal aggregation responses increased the aggregation response by over 2-fold depending on the ADP:A␤ ratios. The structure activity requirements for A␤ activity showed intriguing constraints. Only full length A␤ has significant activity. Truncated A␤ peptides, such as A␤ 1-16 or A␤ 25-35 , or reverse A␤ 40-1 all show little or no activity. We also examined the activity of mutant A␤ peptides, corresponding with the APP 692A→G and APP 693E→Q (at A␤21 and A␤22, respectively) which are found in familial Alzheimer's disease and hereditary cerebral hemorrhagic amyloidosis, Dutch type (HCHWA-D), and found that these peptides showed little or no activity. These results suggest that A␤ interacts with platelets in a highly specific manner and may play a role in regulating platelet function.
Introduction
The ␤-amyloid peptide (A␤) is a 39-42 amino acid peptide that accumulates in the brains of Alzheimer patients and is thought to be the cause of the neurodegeneration underlying Alzheimer's disease (AD). 1 Interestingly, the soluble form of the peptide is constitutively secreted by many cell types and is present in cerebrospinal fluid (CSF) and blood at levels ranging up to 225-625 pM. 2, 3 However, it is unknown whether soluble A␤ has a physiologic function and what that function may be.
Cleavage of amyloid precursor protein (APP) generates the A␤ peptide. The cleavage process is highly regulated so the amount of A␤ secreted can vary greatly, depending on the stimulus. For instance, treatment of cells with muscarinic M1 agonists, such as carbachol, decreases the secretion of A␤ and correspondingly increases secretion of the extracellular domain of APP, termed APP s␣ . One of the cornerstones of the 2 Correspondence to B Wolozin at his present address: Dept of Pharmacology, Loyola University Medical Center, 2160 South First Ave, Maywood, IL 60153, USA. E-mail: bwoloziȰwpo. it.luc.edu Received 26 February 1998; revised and accepted 17 June 1998 amyloid hypothesis of AD is the observation that the mutations in APP that are associated with AD all increase the secretion of varying forms of A␤. Two of these mutations, APP 692A→G (G21) and APP 693E→Q , (Q22), occur directly in the A␤ domain. 4, 5 Previous studies showed that these mutations both increase secretion of A␤, which is presumably the reason for the tremendous accumulation of A␤ in these illnesses. 6 Both of the mutant A␤ peptides show an increased tendency to aggregate, which could contribute to the accumulation of amyloid deposits in the brains of patients with these mutations. 7 The APP 693E→Q mutation, which causes a disease called Hereditary Cerebral Hemorrhagic with Amyloidosis, Dutch type (HCHWA-D), however, is unusual because the pathology shows a large amount of amyloid accumulation in the vasculature and hemorrhage. 8 The hemorrhage is not evident in any other forms of Alzheimer's disease, despite common accumulation of vascular amyloid.
An increasing amount of evidence suggests that low levels of A␤ are indeed functionally active. In PC12 cells and cortical neurons, A␤ potently stimulates tyrosine phosphorylation and activates the lipid kinase, P13 kinase. 9, 10 Under conditions where tyrosine phosphorylation is potentiated, A␤ also induces calcium fluxes. 9, 10 These changes occur rapidly (within seconds to minutes) after application of picomolar and nanomo-lar A␤ and suggest that physiologic levels of A␤ are capable of influencing cellular metabolism.
Micromolar concentrations of fibrillar A␤ have been shown to induce platelet aggregation. 11 Since activation of platelets is associated with tyrosine phosphorylation, we hypothesized that the actions of A␤ in PC12 cells may be relevant to platelet physiology. We now report that physiologic concentrations of A␤ act to augment ADP-mediated platelet aggregation through a mechanism that involves tyrosine phosphorylation.
Materials and methods

Materials
A␤ peptides were obtained from Bachem California and dissolved in H 2 O. The Q22 and G21 mutant forms of A␤ dissolved at 1 mM in stock solutions of 100 mM KHCO 2 , pH 10. All peptides were diluted into Tyrode's buffer prior to the experiments. Fibrillar A␤ , Q22 or G21 peptides were generated by incubating a 0.5-mM solution of the peptide at 37°C for 7 days in PBS. Fibrillar A␤ in PBS was also examined after having been incubated for 24 h at 37°C. Superoxide dismutase and fibrinogen were obtained from Sigma (St Louis, MO, USA).
Platelet isolation
Fresh blood was anticoagulated with 0.1 V 0.1 M sodium citrate, pH 4.5 and 10 M PGE 1 and spun at 700 × g. The platelet-rich plasma was removed and platelets were then isolated by separation on a sepharose CL-2B column using calcium-and magnesium-free Tyrode's buffer (138 mM NaCl, 2.9 mM KCl, 12 mM NaHCO 3 , 0.36 mM NaH 2 PO 4 , 5.5 mM glucose, pH 7.4). The platelet concentration was then measured using an automated cell counter; all assays were performed with platelet solutions containing 1-2 × 10 8 platelets per ml.
Platelet aggregation
Aggregation studies used a Chronolog dual chamber aggregometer. Dual vials were loaded with platelets: calcium (2 mM), magnesium (0.5 mM) and fibrinogen (0.2 mg ml −1 ) were added as needed, and the platelets were warmed in the aggregometer, with stirring, for 2 min at 37°C prior to each test. All experiments were run in tandem with a control platelet vial. During each test, aggregation was recorded on a chart recorder.
Immunoblotting
Forty microliters of platelets were mixed with 10 l of 5× Laemli buffer and frozen until all the samples from a set of experiments had been collected. A separate aliquot from each platelet sample was set aside and frozen for protein analysis by BCA assay (Pierce, Rockford, IL, USA). The platelet/laemli sample buffer mixtures were then incubated at 95°C for 7 min and 40 g was electrophoresed on 8-16% gradient SDS/polyacrylamide gels (NOVEX). The samples were electrophoretically transferred to nitrocellulose, blocked for 1 h in PBS/5% nonfat dry milk and incubated in primary antibody overnight. The blots were then washed 5 × 5 min in PBS/0.05% Triton and incubated overnight in peroxidase-coupled secondary antibody (Jackson Labs). Following a final 5 × 5 min PBS/0.05% Triton X-100 wash, immunoreactivity was visualized using Renaissance chemiluminescent substrate (Dupont).
Cytoskeletal preparations
Following the aggregation trials, 0.5 ml of platelets was mixed with 0.5 ml of 2× NP40 lysis buffer (2% NP40, 20 mM Tris pH 7.4, 40 mM ␤-glycerol diphosphate, 1 mM sodium orthovanadate, 20 g ml −1 leupeptin, 20 g ml −1 aprotinin, 20 mM PMSF) and frozen until all the samples from a set of experiments had been collected. Following completion of the aggregation trials, the platelet lysate solutions were thawed, rocked 20 min at 4°C and spun for 20 min in a microfuge at 12 000 rpm. The supernatants were removed, the detergentinsoluble pellets were washed with 1 ml cold PBS, centrifuged for 10 min at 10 000 × g and the supernatants were removed. The remaining pellets were then taken up in 20 l 5× Laemli sample buffer and immunoblotted as described above. Antibody concentrations were as follows: mouse anti-FAK 1:250 (4 g ml −1 ), Transduction Labs, Lexington, KY, USA), mouse anti-talin 1:1000 (Sigma, St Louis, MO, USA), phosphotyrosine 1:2000 (PY20, Transduction Labs).
Results
A␤ augments platelet aggregation
In order to examine whether physiological levels of A␤ influenced platelet aggregation we studied the effects of A␤ on platelet activity using an aggregometer (Chronolog). We first analyzed the response of platelets to varying doses of A␤ . Although freshly prepared A␤ did induce aggregation alone, addition of A␤ to gel-filtered platelets augmented aggregation induced by adenosine diphosphate (ADP) in Tyrode's buffer containing 2 mM CaCl 2 , 0.5 mM MgCl 2 and 0.2 mg ml affect aggregation mediated by the calcium ionophore A23187 (100 nM), which acts independently of ADP (Figure 1d ). Thus, A␤ augments platelet aggregation through a mechanism than appears to require both ADP and fibrinogen. In order to understand the relationships between A␤ structure and activity, we examined the effect of other A␤ peptides on platelet aggregation. Enhancement of platelet aggregation required the entire A␤ peptide. The A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] peptide was inactive. Similarly, A␤ [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] showed only weak (25%) enhancement of platelet aggregation, and the reverse sequence, A␤ 40-1 , was also inactive. Co-incubation of A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] with A␤ 1-40 prevented the A␤-mediated augmentation of platelet aggregation (Figure 2a ). This blockade of A␤ 1-40 action could be explained either by competition for the two peptides to a specific binding site (in which A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] acts as an antagonist) or by increased aggregation of A␤ with A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , which tends to aggregate more rapidly. In order to determine whether aging or aggregation influences the interaction of A␤ with platelets, we examined the actions of two peptides, A␤ and A␤ , that had been aged for 3 days at 37°C. Both aged A␤ and A␤ were able to augment ADP-induced aggregation at low doses (Figure 2b, A␤ 1-42 shown) . Interestingly, at high concentrations aged A␤ 1-40 and A␤ (1-10 M) were able to induce platelet aggregation in the absence of ADP and fibrinogen, providing that calcium and magnesium were present (Figure 2c) . These results suggest that aging and aggregation of A␤ peptides do not account for the ability of A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] to inhibit the action of A␤ . Rather, the ability of A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] to compete with A␤ suggests that A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] is competing with A␤ 1-40 for a specific binding site on platelets. In order to explore this question further, we investigated whether point mutations in A␤ might also interfere with the interaction of A␤ with platelets. The two peptides used for this study were the A␤ peptide containing the Ala to Gly APP 693 mutation, termed G21, found in rare forms of familial Alzheimer's disease (FAD), and the Glu to Gln APP 692 mutation, termed Q22, found in Hereditary Cerebral Hemorrhagic amyloidosis, Dutch type (HCHWA-D). 4, 5, 12 ADPmediated platelet aggregation was investigated using the G21 or Q22 peptides. The G21 peptide did not augment platelet aggregation at all, while the Q22 peptide had a potency that was less than 10% that of the wildtype peptide (Figure 2d) . Thus, point mutations in the A␤ peptide interfere with its action. These results provide further evidence indicating that augmentation of platelet aggregation by A␤ shows significant constraints related to the structure activity requirements.
Molecular correlates of A␤ actions
Since platelet aggregation is known to be associated with reorganization of the cytoskeleton which is associated with translocation of proteins, such as talin or focal adhesion kinase (FAK), to the cytoskeleton, 13 we felt that A␤ may also augment translocation of FAK or talin to the cytoskeleton. Platelets were incubated for 3 min at 37°C with varying doses of A␤, ADP or both and the cytoskeletons were isolated and immunoblotted with an anti-talin antibody as described in Methods. Nanomolar levels of A␤ augmented the association of talin with the cytoskeleton in a dosedependent manner ( Figure 3a) ; as with the aggregation studies, incubation of platelets with A␤ in the absence of ADP has no effect on the translocation of talin. Similarly, A␤ 1-40 also increased the association of the FAK (125 kDa) with the cytoskeleton (Figure 3b) ; in separate experiments A␤ 1-42 also increased cytoskeletal FAK [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] progressively inhibited translocation of FAK to the cytoskeleton induced by A␤ . The bands at 50 and 70 kDa may represent proteolytic breakdown products of FAK or cross-reactive proteins. 27 (d) In studies of FAK translocation, G21 also showed no activity while Q22 showed reduced activity.
(data not shown). As seen with the augmentation studies, the actions of A␤ on FAK could be competed away by incubation with excess amounts of A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (Figure  3b ). A␤ did not augment FAK translocation induced by the calcium ionophore A23187. Since tyrosine phosphorylation of FAK is thought to be important for its translocation to the cytoskeleton, we also examined the effects of A␤ on platelet tyrosine phorphorylation. Platelets were treated as above and cytoskeletons were isolated and immunoblotted with the anti-phoshotyrosine antibody, PY20, as described in Methods. Treatment of platelets with A␤ augmented the phosphorylation of a 125-kDa protein, which is a size characteristic of FAK, present in the cytoskeletal fraction (Figure 3c ). Co-incubation of the platelets with A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] competed away the effects of A␤ .
Finally, we also examined the effects of the mutant Q22 and G21 A␤ peptides on FAK translocation. Platelets were incubated for 3 min at 37°C in Tyrode's buffer (containing 2 mM CaCl 2 , 0.5 mM MgCl 2 , 0.2 mg ml −1 fibrinogen and 1 M ADP) with varying doses of A␤, Q22 or G21 and the cytoskeletons were isolated and immunoblotted with an anti-FAK antibody as described in Methods. As shown in Figure 3d , FAK did not translocate to the cytoskeleton in response to the G21. Similarly, FAK showed only weak cytoskeletal translocation in response to the Q22 peptide ( Figure  3d ). In contrast, A␤ 1-40 strongly stimulated FAK translocation (Figure 3d) . Thus, the actions of the mutant G21 and Q22 A␤ peptides in the FAK translocation assay paralleled results seen in the platelet aggregation assay (Figure 2c ).
A␤ induces actions independent of ADP
Although A␤ does not appear to induce changes in the cytoskeleton in the absence of ADP, analysis of total lysates from platelets did show changes induced by A␤ that did not require ADP. Platelets were incubated for 2 min with varying doses of A␤ 1-40 in Tyrode's buffer containing calcium, magnesium, indomethacin and apyrase, but no ADP or fibrinogen. The apyrase and indomethacin were added to inactivate any ADP that might be present and to prevent aggregation, in order to ensure that any effects seen were due to addition of A␤. The cells were then lysed and immunoblotted with the anti-phosphotyrosine antibody, PY20. The A␤-treated platelets showed a strong band in the range of 180-200 kDa and a weaker band at 140 kDa (Figure 4) , both of which appeared in a dose-dependent manner. Thus, low doses of A␤ can induce changes in the platelets independent of ADP.
Discussion
This study shows that nanomolar levels of A␤ can affect platelets' metabolism by enhancing aggregation induced by ADP. The effects of A␤ are evident in both physiological experiments directly monitoring platelet aggregation and in biochemical experiments analyzing the platelet cytoskeleton. Unlike many experiments done with A␤, these studies show that the interaction of A␤ with platelets is highly specific. Neither the reverse A␤ peptide nor smaller A␤ fragments are active. Moreover, point mutations in the A␤ peptides, such as those associated with familial AD or HCHWA-D, markedly diminish the activity of A␤.
The structure activity data suggest that the interaction of A␤ with platelets is associated with a specific binding site rather than a nonspecific membrane-A␤ interaction. The ability of the A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] peptide to compete with A␤ 1-40 supports this suggestion since specific binding is subject to competition, while non-specific binding is non-competitive. The competition of A␤ actions by A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] is a robust observation, being evident not only in tracings of platelet aggregation, but also in biochemical analyses of FAK translocation to the cytoskeleton and FAK tyrosine phosphorylation. Although the data are most consistent with the presence of a specific binding site on platelets that can be competed away with A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , two alternate hypotheses are conceivable: (1) that A␤ binds directly to ADP; and (2) that aggregation of A␤ somehow augments the actions of ADP. Both of these possibilities, though, appear unlikely. The stochiometry of the A␤-ADP actions argue against a direct interaction of A␤ with ADP. The actions of A␤ plateau 100-1000 fold below the concentration of ADP needed to induce aggregation. If A␤ were directly interacting with ADP, rather than recognizing a specific A␤ platelet-binding site, then A␤ would enhance ADP aggregation with a dose response curve for A␤ approaching 1 M, the concentrations of ADP used in the assays. An alternate possibility, which could explain the competition by A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , is that the increased tendency of A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] to aggregate somehow interferes with the action of A␤, separate from an interaction with platelets. However, since aged A␤ or A␤ 1-42 both augment platelet aggregation as well as fresh A␤, we feel that the potential stimulation of A␤ aggregation by A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] does not account for its ability to inhibit the actions of A␤ .
The narrow structure activity requirements of the A␤/platelet interaction support the notion of a specific binding site on platelets for A␤. The actions of A␤ show great selectivity in that only A␤ 1-40 is active, shorter fragments of A␤ and a peptide with the reverse sequence are inactive, while the A␤ [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] peptide is only 25% active. Moreover, point mutations alter the activity of A␤, with the G21 mutant showing no activity and the Q22 mutant showing a 90% reduction in platelet-directed activity. Thus, the conclusion that A␤ is interacting with a specific binding site on platelets appears reasonable.
Another aspect of this study that has proved to be particularly useful in our investigations of A␤ actions is the regulation of protein translocation to the cytoskeleton. Previous studies outlining the mechanism of platelet aggregation have shown that the cytoskeleton extensively reorganizes during platelet aggregation in a process that appears to be mediated by the binding of proteins such as FAK and talin to focal adhesion points in the cytoskeleton. [13] [14] [15] Platelet-activating agents, such as ADP, epinephrine or thrombin, stimulate tyrosine phosphorylation and activation of FAK which then binds to focal adhesion points on the cytoskeleton and appears to induce the cytoskeletal reorganization that results in platelet flattening and adherence. 13, 14 The actions of A␤ on platelets are clearly seen when examining the FAK pathway. Wildtype A␤ greatly augments ADP-mediated translocation of FAK, and talin, to the cytoskeleton; the G21 and Q22 mutant A␤ peptides show little or no activity. The effects of aggregated A␤ on FAK translocation are similar to those seen by Zhang et al in SY5Y cells in which micromolar doses of aggregated A␤ are shown to induce translocation of FAK to the cytoskeleton over a 24-h time course. 16 Since FAK and talin normally translocate to the cytoskeleton during platelet aggregation, our study does not address whether these events mediate the actions of A␤. However, cytoskeletal translocation of FAK and talin are clearly excellent markers for A␤ activity.
Whether A␤ normally functions as a physiological regulator of platelet aggregation remains to be determined. The steady state concentration of A␤ in serum has been measured at between 0.03-0.6 nM, depending on the study. 2, 17 This suggests that the steady state concentration of A␤ in serum may be below the level determined in our study at which A␤ acts on platelets. However, since APP processing changes during platelet aggregation, it is possible that the local concentration of A␤ rises transiently when platelets are activated.
18 Thus, the steady state level of A␤ in serum may not be an accurate indication of the exposure of platelets to A␤. Many agents, such as thrombin or acetylcholine are known to alter A␤ processing. Any transient increases in serum A␤ levels might achieve concentrations of A␤ sufficient to promote platelet aggregation. A critical question remaining is to identify the putative receptor on platelets with which A␤ is interacting. An increasing number of studies have pointed to proteins that can bind A␤ either with high affinity, such as the RAGE or ERAB receptors, or bind A␤ with lower affinities but mediate defined actions, such as Fyn, which stimulates tyrosine phosphorylation, or the p75 NGF receptor which stimulates NGF signaling and also cell death pathways. 16, 19, 20 Being a tyrosine kinase that associates with FAK, fyn is a particularly interesting potential target for A␤. 21 The diseases associated with the APP 692 and APP 693 mutations appear to largely result from changes in the processing of APP which lead to increased production of A␤ and its subsequent accumulation. 6 However, the altered biological function associated with the mutant A␤ peptides in these diseases could contribute to some of the differences between the pathology of these illnesses and that of classic AD. It is intriguing to speculate that the inability of the HCHWA-D A␤ peptide to augment platelet aggregation contributes to hemorrhagic pathology associated with the illness. Cases of HCHWA-D tend to have a larger amount of vascular amyloid deposition than do cases of AD or familial AD (such as those associated with APP 692 mutation). 22 The increased production of A␤ associated with the APP 693 mutation leads to extensive vascular deposition of A␤. Since inhibition of ADP action inhibits platelet aggregation, vascular deposition of the mutant A␤ peptide would increase vascular concentrations of the mutant A␤ and potentially reduce platelet aggregation, which could contribute to the hemorrhage. 23 Our observations of the losses of function associated with these mutations also raise the possibility that other actions of A␤, such as the regulation of potassium channel conductance or generation of free radicals, may also be sensitive to the point mutations in the A␤ peptide that are associated with familial AD and HCHWA-D. [24] [25] [26] Such mutation-related changes could also contribute to the pathophysiology of the diseases caused by these mutations.
